Ionis Pharmaceuticals, Inc. Increase (Decrease) in Deferred Revenue
Ionis Pharmaceuticals, Inc. (IONS) reported Increase (Decrease) in Deferred Revenue of $36.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-02-28
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$5.40M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$27.11M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$12.23M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was $81.43M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for fiscal 2017 was $36.70M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for fiscal 2016 was -$59.15M, a 367.43% decline from fiscal 2015.
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for fiscal 2015 was $22.12M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in deferred revenue for fiscal 2014 was -$11.41M, a 112.92% decline from fiscal 2013.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$32.51M derived: sum of 2 quarters · filed 2018-02-28 | -$44.74M derived: sum of 3 quarters · filed 2018-02-28 | $36.70M 10-K · filed 2018-02-28 |
| 2017-09-30 | -$27.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$39.34M derived: sum of 2 quarters · filed 2017-11-07 | $42.09M 10-Q · filed 2017-11-07 | $26.20M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-06-30 | -$12.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $69.20M 10-Q · filed 2017-08-09 | $53.31M derived: sum of 3 quarters · filed 2018-02-28 | $40.77M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-03-31 | $81.43M 10-Q · filed 2017-05-09 | $65.54M derived: sum of 2 quarters · filed 2018-02-28 | $53.00M derived: sum of 3 quarters · filed 2018-02-28 | $37.13M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-12-31 | -$15.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$28.43M derived: sum of 2 quarters · filed 2018-02-28 | -$44.30M derived: sum of 3 quarters · filed 2018-02-28 | -$59.15M 10-K · filed 2018-02-28 |
| 2016-09-30 | -$12.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$28.41M derived: sum of 2 quarters · filed 2017-11-07 | -$43.26M 10-Q · filed 2017-11-07 | -$58.87M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | -$15.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$30.72M 10-Q · filed 2017-08-09 | -$46.33M derived: sum of 3 quarters · filed 2018-02-28 | $4.50M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | -$14.85M 10-Q · filed 2017-05-09 | -$30.46M derived: sum of 2 quarters · filed 2018-02-28 | $20.37M derived: sum of 3 quarters · filed 2018-02-28 | $15.11M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | -$15.61M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $35.22M derived: sum of 2 quarters · filed 2018-02-28 | $29.96M derived: sum of 3 quarters · filed 2018-02-28 | $22.12M 10-K · filed 2018-02-28 |
| 2015-09-30 | $50.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $45.57M derived: sum of 2 quarters · filed 2016-11-09 | $37.73M 10-Q · filed 2016-11-09 | $54.90M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$5.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$13.10M 10-Q · filed 2016-08-09 | $4.07M derived: sum of 3 quarters · filed 2017-03-01 | -$5.53M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$7.84M 10-Q · filed 2016-05-05 | $9.33M derived: sum of 2 quarters · filed 2017-03-01 | -$278.00K derived: sum of 3 quarters · filed 2017-03-01 | -$13.51M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $17.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $7.56M derived: sum of 2 quarters · filed 2017-03-01 | -$5.67M derived: sum of 3 quarters · filed 2017-03-01 | -$11.41M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$9.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$22.84M derived: sum of 2 quarters · filed 2015-11-09 | -$28.58M 10-Q · filed 2015-11-09 | -$44.64M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | -$13.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$18.98M 10-Q · filed 2015-08-05 | -$35.04M derived: sum of 3 quarters · filed 2016-02-26 | $56.35M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | -$5.74M 10-Q · filed 2015-05-05 | -$21.80M derived: sum of 2 quarters · filed 2016-02-26 | $69.59M derived: sum of 3 quarters · filed 2016-02-26 | $91.12M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | -$16.06M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $75.33M derived: sum of 2 quarters · filed 2016-02-26 | $96.86M derived: sum of 3 quarters · filed 2016-02-26 | $88.34M 10-K · filed 2016-02-26 |
| 2013-09-30 | $91.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $112.92M derived: sum of 2 quarters · filed 2014-11-07 | $104.40M 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $21.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $13.01M 10-Q · filed 2014-08-04 | ||
| 2013-03-31 | -$8.52M 10-Q · filed 2014-05-06 | |||
| 2012-12-31 | $48.52M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | -$70.86M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | -$46.81M 10-K · filed 2013-02-28 | |||
| 2009-12-31 | -$82.65M 10-K · filed 2012-02-29 | |||
| 2008-12-31 | $210.97M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |